Physician profile
Jerome Pierson
NPI 1659345668
$2,460.34
in general payments reported to CMS, 2019-2025
25 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $194 · 2021: $425 · 2022: $723 · 2023: $326 · 2024: $361 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $325.81 | 2019-2025 | |
| Boston Scientific Corporation | $223.68 | 2019-2025 | General - Therapies, Eluvia, Mylux Patient Kit With Mobile Device |
| Actelion Pharmaceuticals US, INC. | $198.00 | 2022 | |
| Abbott Laboratories | $194.65 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $181.71 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $165.42 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.84 | 2020-2025 | Jardiance |
| Medtronic, INC. | $151.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $149.32 | 2020-2025 | Eliquis, Camzyos |
| Impulse Dynamics (USA) INC. | $140.73 | 2022 | |
| Inari Medical, INC. | $110.51 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $66.88 | 2019-2023 | Repatha |
| Conmed Corporation | $66.67 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $56.63 | 2023-2024 | Inpefa |
| Cardiovascular Systems INC. | $47.75 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.27 | 2019-2022 | |
| Cardiva Medical, INC. | $33.02 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Astrazeneca Pharmaceuticals LP | $30.83 | 2019-2020 | |
| Chiesi USA, INC. | $21.48 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.70 | 2022 | |
| Scpharmaceuticals INC. | $17.60 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.12 | 2024 | Lifevest |
| Irhythm Technologies, INC. | $13.68 | 2020 | |
| Esperion Therapeutics, INC. | $12.57 | 2022 | |
| Medtronic Vascular, INC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Pierson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.